Navigation Links
DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
Date:3/24/2008

betic retinopathy, of which diabetic macular edema is the primary cause of vision loss. In the United States, as many as 200,000 people are diagnosed with DME each year and an estimated 1,000,000 people suffer from DME. Currently, there are no FDA approved drug treatments for DME.

A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing studies. The FAME DSMB, a group comprised of four ophthalmologists and a biostatistician, met to review the Medidur FA Phase III clinical trial data. The DSMB's charter stipulates that a formal review occur every six months in addition to their ongoing review of the trial.

About Alimera Sciences Inc.

Alimera Sciences Inc. is singularly focused on the development and commercialization of prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patients' lives and strengthen physicians' ability to manage ocular conditions.

Alimera completed enrollment in October 2007 of its 956-patient Phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. Alimera has also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment for ophthalmic diseases. The agreement gives Alimera the exclusive option to license compounds which are NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera retains the right to use the Medidur delivery sy
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... financial results for the second quarter ended June ... to see encouraging advancements in the US commercialization ... estimated total prescriptions and estimated total per week ... Arena,s President and Chief Executive Officer. "Other recent ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26
(Date:8/1/2014)... (PRWEB) August 01, 2014 Growing ... coverage and healthcare reforms are boosting healthcare market ... medicines through discounts and increasing generic consumption is ... approximately 76.7 million in 2013, having grown at ... from 2008. The implementation of the Health Transformation ...
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by ... Oxide, Titanium Dioxide, and Zinc Omadine), Application (Indoor ... & Beverages, Textiles, and others), & Geography (North ... and Forecasts to 2018" analyzes the Antimicrobial Coatings ... trends in the diverse geographical regions. , Browse ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. ... as a time-honored destination for a good cut and conversation. ... also be the spot to tackle an often overlooked health ... novel partnership, the U.S. Centers for Disease Control and Prevention, ... the help of barbershop staff to both discuss and diagnose ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
Breaking Medicine News(10 mins):Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4
... activates p53 tumor-suppressor function without causing DNA damage , , ... targets a protein interaction involved in many types of ... , In cell cultures, the small-molecule inhibitor MI-219 was ... protein p53 from being blocked in the presence of ...
... of Telehealth capabilities to the ... they help across Canada., TORONTO, March 7 /PRNewswire/ - ... announce they have partnered with We,Care Health Services Inc. "We ... of services for those with chronic diseases,and their caregivers. We ...
... HOLLYWOOD, Fla., March 7, Cancer,s two ... "costs," and each holds capacity,to create patient ... the National Comprehensive Cancer Network,s 13th Annual,Conference, ... treatments, best practices dictate that,they follow guidelines ...
... Grey House Publishing and Penn,Hill Publications, based in ... Hudson,s Washington News Media Contacts Directory. In addition ... Media Contacts,Directory, Grey House is also proud to ... Directory., In 1968, Howard Penn Hudson completed ...
... Galderma Pharma, S.A.,announces an agreement with ZARS ... outside the USA and Canada for promotion and,distribution ... follows,an agreement signed last year between Galderma and ... in the USA and Canada., "This agreement ...
... The rheumatoid arthritis (RA),treatment market, held back somewhat in ... and Bextra, is rebounding due to the,performance of biologic ... $12 billion in 2006 and -- driven by new ... year through 2011,according to a new report by Kalorama ...
Cached Medicine News:Health News:Researchers Design Promising Cancer Drug 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 3Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 2Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 3Health News:Grey House Publishing Acquires Hudson's Washington News Media Contacts Directory 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 3Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2
... collect sample, pipette into testing wells ... FDA 510K cleared multiple drug screen ... both drugs and adulterants. It can ... (5) drugs and can be accompanied ...
... Glucose Monitoring System is a patient insertable short-term ... the DexCom STS Receiver., The DexCom STS Sensor ... the DexCom STS Applicator by the user or ... held in place by an adhesive to the ...
... routine Holter,monitoring, the Burdick Vision ... a,practical, no-nonsense diagnostic tool ideal,for ... This highly accurate and,easy-to-use system ... configurations at a price even ...
... PC-based ECG diagnostics complements transition to ... the incorporation of computer-based technology into ... diagnostic instrumentation have developed. Burdick's Universal ... EMRs making it the ideal choice ...
Medicine Products: